Cytokinetics Total Current Liabilities from 2010 to 2024

CYTK Stock  USD 50.25  1.15  2.34%   
Cytokinetics Total Current Liabilities yearly trend continues to be quite stable with very little volatility. Total Current Liabilities may rise above about 107.8 M this year. Total Current Liabilities is the total amount of liabilities that Cytokinetics is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. View All Fundamentals
 
Total Current Liabilities  
First Reported
2002-12-31
Previous Quarter
102.8 M
Current Value
109.8 M
Quarterly Volatility
25.3 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Cytokinetics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cytokinetics' main balance sheet or income statement drivers, such as Interest Expense of 60.6 M, Other Operating Expenses of 528.9 M or Research Development of 334.1 M, as well as many indicators such as Price To Sales Ratio of 1.1 K, Dividend Yield of 0.0 or Days Sales Outstanding of 59.08. Cytokinetics financial statements analysis is a perfect complement when working with Cytokinetics Valuation or Volatility modules.
  
Check out the analysis of Cytokinetics Correlation against competitors.
For more information on how to buy Cytokinetics Stock please use our How to buy in Cytokinetics Stock guide.

Latest Cytokinetics' Total Current Liabilities Growth Pattern

Below is the plot of the Total Current Liabilities of Cytokinetics over the last few years. Total Current Liabilities is an item on Cytokinetics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Cytokinetics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. Cytokinetics' Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cytokinetics' overall financial position and show how it may be relating to other accounts over time.
Total Current Liabilities10 Years Trend
Slightly volatile
   Total Current Liabilities   
       Timeline  

Cytokinetics Total Current Liabilities Regression Statistics

Arithmetic Mean40,933,993
Geometric Mean28,466,494
Coefficient Of Variation82.80
Mean Deviation27,097,457
Median31,199,000
Standard Deviation33,894,706
Sample Variance1148.9T
Range103.2M
R-Value0.87
Mean Square Error294.7T
R-Squared0.76
Significance0.000022
Slope6,615,176
Total Sum of Squares16083.9T

Cytokinetics Total Current Liabilities History

2024107.8 M
2023102.7 M
202284.6 M
202171.9 M
202031.2 M
201926 M
201822.2 M

About Cytokinetics Financial Statements

Cytokinetics investors utilize fundamental indicators, such as Total Current Liabilities, to predict how Cytokinetics Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Total Current Liabilities102.7 M107.8 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Cytokinetics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Cytokinetics Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Cytokinetics Stock. Highlighted below are key reports to facilitate an investment decision about Cytokinetics Stock:
Check out the analysis of Cytokinetics Correlation against competitors.
For more information on how to buy Cytokinetics Stock please use our How to buy in Cytokinetics Stock guide.
You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. If investors know Cytokinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytokinetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(5.51)
Revenue Per Share
0.03
Quarterly Revenue Growth
0.225
Return On Assets
(0.30)
Return On Equity
(5.72)
The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytokinetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytokinetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytokinetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.